Minnesota is currently home to 2098 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Waveform Capnography Compared to Colorimetric Carbon Dioxide Detection During Tracheal Intubation of Critically Ill Adults
NCT06934876
Recruiting
This study will compare the sensitivity and specificity of waveform capnography versus colorimetric carbon dioxide detection to identify tracheal placement of the endotracheal tube during intubation of critically ill adults.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: Hennepin Healthcare, Minneapolis, Minnesota
Conditions: Acute Respiratory Failure
Register for Updates
A Single-arm, Pivotal Study to Evaluate Acute Device and Technical Success of the CGuard Prime Carotid Stent System When Used in Conjunction to the ENROUTE Transcarotid Neuroprotection System in Patients Undergoing Carotid Artery Stenting Via the Transcarotid Artery Revascularization Approach
NCT06653387
Recruiting
The objective of this study is to evaluate acute device and technical success of the CGuard Prime™ Carotid Stent System (80cm) when used in conjunction with the Enroute NPS during Transcarotid Artery Revascularization procedures in the treatment of carotid artery stenosis in spatients at high risk for adverse events from carotid endarterectomy.
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
05/30/2025
Locations: Allina, Minneapolis, Minnesota
Conditions: Carotid Artery Diseases
Register for Updates
Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
NCT06605378
Recruiting
This research study is designed to assess the prevalence of specific antibodies and inflammatory cytokines in adult and pediatric participants with CGD.
Gender:
ALL
Ages:
All
Trial Updated:
05/30/2025
Locations: Home-based telemedicine, St. Paul, Minnesota
Conditions: Chronic Granulomatous Disease (CGD)
Register for Updates
An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
NCT06129240
Recruiting
Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 \& 3 PH.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/30/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Pulmonary Hypertension, Interstitial Lung Disease
Register for Updates
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
NCT06119685
Recruiting
This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumumab or rituximab to evaluate the safety, tolerability and preliminary antitumor activity in patients with advanced hematologic cancers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: NHL, Multiple Myeloma, Blood Cancer, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Register for Updates
The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction
NCT05499702
Recruiting
Caloric restriction (and RYGB) improves insulin action and lowers fasting glucose, glucagon and EGP, without changes in postprandial EGP and glucagon concentrations. Caloric restriction also improves hepatic steatosis and lowers fasting AA. These changes may represent restoration of glucagon's hepatic actions. This experiment will determine whether caloric restriction improves glucagon's actions on hepatic amino acid, carbohydrate and lipid metabolism in T2DM in comparison to a baseline experime... Read More
Gender:
ALL
Ages:
Between 25 years and 65 years
Trial Updated:
05/30/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Type2diabetes
Register for Updates
Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion
NCT05264727
Recruiting
This study is being done to better understand how amino acids alter the release of glucagon and insulin compared to glucose alone in health and disease.
Gender:
ALL
Ages:
Between 25 years and 65 years
Trial Updated:
05/30/2025
Locations: Mayo Clinic Rochester, Rochester, Minnesota
Conditions: Healthy, Type 2 Diabetes, Obesity
Register for Updates
Nonopioid Pain Control Regimen After Arthroscopic Hip Procedures
NCT05076110
Recruiting
This study is being conducted to evaluate the effectiveness of post-operative pain control without using narcotic pain medications.
Gender:
ALL
Ages:
Between 16 years and 60 years
Trial Updated:
05/30/2025
Locations: Mayo clinic, Rochester, Minnesota
Conditions: Hip Arthroscopy
Register for Updates
TTVR Early Feasibility Study
NCT04433065
Recruiting
The objective of this early feasibility study is to gain early clinical insight into the performance of the Intrepid transcatheter tricuspid valve replacement (TTVR) system intended for transfemoral access to deliver a self-expanding bioprosthetic valve within the tricuspid valve.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: Abbott Northwestern Hospital, Minneapolis, Minnesota
Conditions: Tricuspid Regurgitation
Register for Updates
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
NCT06603844
Recruiting
The purpose of this study is to determine the safety, blood concentrations and treatment effect of CRB-601 in combination with immunotherapy in patients who have advanced solid tumors (cancer) and have exhausted other therapeutic options.CRB-601 targets a protein called avb8 integrin which is expressed by some cancers and not others. This study will focus on tumor types which are know to highly or moderately express this protein. Researchers will evaluate the side effects caused by treatment, l... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: SCRI - Minnesota Oncology Hematology, Maple Grove, Minnesota
Conditions: Solid Tumor
Register for Updates
Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects
NCT06471543
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of single doses of RN0361 in Adult healthy subjects and Adult Hypertriglyceridemic Subjects.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/29/2025
Locations: Axis Clinicals USA, Dilworth, Minnesota
Conditions: Hypertriglyceridemia, Familial Chylomicronemia Syndrome
Register for Updates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
NCT06161584
Recruiting
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Gender:
ALL
Ages:
60 years and above
Trial Updated:
05/29/2025
Locations: Retina Consultants of Minnesota, PLLC (01-025), Edina, Minnesota
Conditions: Geographic Atrophy
Register for Updates